CD47 and neoplasm: This mechanism has shown promise in both preclinical models and clinical applications.[187, 188, 207, 208] However, caution is advised as CD47 is also present in erythrocytes and normal cells in vivo, necessitating consideration of potential off‐target effects when utilizing CD47 antibodies.[205] Despite this, the utilization of anti‐CD47 monoclonal antibodies in tumor treatment is yielding encouraging outcomes.[188, 207]